Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 23, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 21 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 8 concluded trials, 75% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 23, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 30, 2027 | Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG | Trial Milestone | Phase 1 |
| June 30, 2027 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | Trial Milestone | Phase 1 |
| February 15, 2028 | Phase 1 Study of CLR 125 in Triple Negative Breast Cancer | Trial Milestone | Phase 1 |
| January 15, 2032 | Evaluation of Iopofosine I 131 vs. R-CD in WM Patients | Trial Milestone | Phase 3 |
Track CLRB alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CLRB in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.